U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07263594) titled 'A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors' on Nov. 17.
Brief Summary: This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Gastrointestinal Cancer
Intervention:
DRUG: DB-1324
Administered I.V.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: DualityBio Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....